NCT00411788View on ClinicalTrials.gov

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Breast Cancer
Interventions
DRUG

Rapamycin

oral rapamycin 6 mg daily

DRUG

Trastuzumab

Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.

Trial Locations (2)

06610

Bridgeport Hospital, Bridgeport

06519

Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Yale University

OTHER

NCT00411788 - A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter